

Luciana Ansanelli Naves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4006145/publications.pdf>

Version: 2024-02-01

79
papers

3,653
citations

172207

29
h-index

133063

59
g-index

89
all docs

89
docs citations

89
times ranked

2744
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line <i>AIP</i> Mutations and Pituitary Adenomas: An International Collaborative Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E373-E383.	1.8	323
2	Gigantism and Acromegaly Due to Xq26 Microduplications and <i>GPR101</i> Mutation. <i>New England Journal of Medicine</i> , 2014, 371, 2363-2374.	13.9	292
3	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1891-1896.	1.8	283
4	Acromegaly: clinical features at diagnosis. <i>Pituitary</i> , 2017, 20, 22-32.	1.6	176
5	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. <i>European Journal of Endocrinology</i> , 2012, 167, 651-662.	1.9	173
6	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. <i>Endocrine-Related Cancer</i> , 2015, 22, 745-757.	1.6	155
7	High prevalence of <i>AIP</i> gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. <i>European Journal of Endocrinology</i> , 2011, 165, 509-515.	1.9	152
8	X-linked acrogigantism syndrome: clinical profile and therapeutic responses. <i>Endocrine-Related Cancer</i> , 2015, 22, 353-367.	1.6	151
9	Expression of aryl hydrocarbon receptor (<i>AHR</i>) and <i>AHR</i> -interacting protein in pituitary adenomas: pathological and clinical implications. <i>Endocrine-Related Cancer</i> , 2009, 16, 1029-1043.	1.6	134
10	Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. <i>Pituitary</i> , 2010, 13, 123-129.	1.6	122
11	Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. <i>Pituitary</i> , 2016, 19, 448-457.	1.6	108
12	Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 436-444.	1.8	97
13	Selenoprotein-Related Disease in a Young Girl Caused by Nonsense Mutations in the <i>SBP2</i> Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4066-4071.	1.8	89
14	Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. <i>European Journal of Endocrinology</i> , 2007, 157, 383-391.	1.9	84
15	Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. <i>Endocrine-Related Cancer</i> , 2016, 23, 221-233.	1.6	75
16	Cyclin-dependent kinase inhibitor 1B (<i>CDKN1B</i>) gene variants in <i>AIP</i> mutation-negative familial isolated pituitary adenoma kindreds. <i>Endocrine-Related Cancer</i> , 2012, 19, 233-241.	1.6	72
17	Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 236-263.	0.3	69
18	Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. <i>Pituitary</i> , 2015, 18, 385-394.	1.6	65

#	ARTICLE	IF	CITATIONS
19	Nelson's Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment. <i>Hormone Research in Paediatrics</i> , 2004, 62, 300-305.	0.8	57
20	Polycystic ovary syndrome and hyperprolactinemia are distinct entities. <i>Gynecological Endocrinology</i> , 2007, 23, 267-272.	0.7	55
21	Pitfalls in the diagnosis of Cushing's syndrome. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1207-1216.	1.3	49
22	Increase of Classic and Nonclassic Cardiovascular Risk Factors in Patients with Acromegaly. <i>Endocrine Practice</i> , 2007, 13, 363-372.	1.1	49
23	Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. <i>Pituitary</i> , 2011, 14, 148-156.	1.6	47
24	Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. <i>Endocrine</i> , 2016, 51, 236-244.	1.1	45
25	The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	0.6	40
26	Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. <i>Pituitary</i> , 2013, 16, 189-194.	1.6	38
27	Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone β subunit mutation. <i>Fertility and Sterility</i> , 2008, 90, 1169-1174.	0.5	35
28	Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience. <i>Pituitary</i> , 2009, 12, 165-169.	1.6	32
29	The role of non-invasive dynamic tests in the diagnosis of Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 1008-1013.	1.8	28
30	Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. <i>Endocrine</i> , 2014, 46, 577-584.	1.1	22
31	Lack of acute zinc effects in glucose metabolism in healthy and insulin-dependent diabetes mellitus patients. <i>BioMetals</i> , 1999, 12, 161-166.	1.8	21
32	Mean intrasellar pressure, visual field, headache intensity and quality of life of patients with pituitary adenoma. <i>Arquivos De Neuro-Psiquiatria</i> , 2010, 68, 350-354.	0.3	21
33	Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 761-767.	1.3	21
34	Substantial Shrinkage of Adenomas Cosecreting Growth Hormone and Prolactin with use of Cabergoline Therapy. <i>Endocrine Practice</i> , 2007, 13, 396-402.	1.1	20
35	A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. <i>Archives of Endocrinology and Metabolism</i> , 2016, 60, 374-390.	0.3	20
36	Adrenal Incidentalomas: Diagnostic Evaluation and Long-Term Follow-up. <i>Endocrine Practice</i> , 2008, 14, 269-278.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Predição da síndrome metabólica em crianças por indicadores antropométricos. Arquivos Brasileiros De Cardiologia, 2011, 96, 121-125.	0.3	19
38	Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly. Pituitary, 2015, 18, 8-15.	1.6	17
39	Incidence of Obesity Does Not Appear to Be Increased after Treatment of Acute Lymphoblastic Leukemia in Brazilian Children: Role of Leptin, Insulin, and IGF-1. Hormone Research in Paediatrics, 2007, 68, 164-170.	0.8	16
40	Brazilian multicenter study on pegvisomant treatment in acromegaly. Archives of Endocrinology and Metabolism, 2019, 63, 328-336.	0.3	16
41	Clinical and genetic aspects of familial isolated pituitary adenomas. Clinics, 2012, 67, 37-41.	0.6	14
42	Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing's disease in Brazil. Archives of Endocrinology and Metabolism, 2016, 60, 267-286.	0.3	14
43	Thromboelastometry demonstrates endogenous coagulation activation in nonsevere and severe COVID-19 patients and has applicability as a decision algorithm for intervention. PLoS ONE, 2022, 17, e0262600.	1.1	14
44	Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up. International Journal of Endocrinology, 2016, 2016, 1-14.	0.6	13
45	Cognitive-behavioral therapy improves the quality of life of patients with acromegaly. Pituitary, 2018, 21, 323-333.	1.6	13
46	Medical combination therapies in Cushing's disease. Pituitary, 2015, 18, 253-262.	1.6	12
47	Association between variations of physiological prolactin serum levels and the risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2020, 166, 108247.	1.1	12
48	Management of prolactinomas in Brazil: an electronic survey. Pituitary, 2010, 13, 199-206.	1.6	11
49	Avaliação da atividade física na prática de vida diária comparada com o nível de atividade da doença em pacientes acromegálicos: impacto na percepção da qualidade de vida. Arquivos Brasileiros De Endocrinologia E Metabologia, 2013, 57, 550-557.	1.3	11
50	Nonthyroidal illness syndrome in patients with subarachnoid hemorrhage due to intracranial aneurysm. Arquivos De Neuro-Psiquiatria, 2004, 62, 26-32.	0.3	9
51	Clinical and laboratorial characterization and post-surgical follow-up of 87 patients with non-functioning pituitary macroadenomas. Arquivos De Neuro-Psiquiatria, 2013, 71, 307-312.	0.3	9
52	Armadilhas no diagnóstico da hiperprolactinemia. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 347-357.	1.3	8
53	Distúrbios na secreção e ação do hormônio antidiurético. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 467-481.	1.3	8
54	Using clinical data to predict sleep hypoxemia in patients with acromegaly. Arquivos De Neuro-Psiquiatria, 2007, 65, 234-239.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up. <i>Hormone Research in Paediatrics</i> , 2018, 89, 63-70.	0.8	7
56	Transient Elastography and Controlled Attenuation Parameter (CAP) in the Assessment of Liver Steatosis in Severe Adult Growth Hormone Deficiency. <i>Frontiers in Endocrinology</i> , 2019, 10, 364.	1.5	7
57	Implementation and Monitoring of a Telemedicine Model in Acromegalic Outpatients in a Low-Income Country During the COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2021, 27, 905-914.	1.6	7
58	Craniofacial abnormalities, obesity, and hormonal alterations have similar effects in magnitude on the development of nocturnal hypoxemia in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 1052-1057.	1.8	6
59	The Brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 833-841.	1.3	6
60	Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases. <i>Frontiers in Endocrinology</i> , 2018, 9, 625.	1.5	6
61	The Effect of Cognitive-Behavioral Therapy on Acromegalics After a 9-Month Follow-Up. <i>Frontiers in Endocrinology</i> , 2019, 10, 380.	1.5	6
62	Tratamento medicamentoso dos tumores hipofisários. Parte I: prolactinomas e adenomas secretores de GH. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2000, 44, 367-381.	1.3	6
63	Prevalence of lung structure abnormalities in patients with acromegaly and their relationship with gas exchange: cross-sectional analytical study with a control group. <i>Sao Paulo Medical Journal</i> , 2015, 133, 394-400.	0.4	5
64	Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 212-230.	0.3	5
65	Tratamento medicamentoso dos tumores hipofisários. parte II: adenomas secretores de ACTH, TSH e adenomas clinicamente não-funcionantes. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2000, 44, 455-470.	1.3	4
66	Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR. <i>Pharmacoeconomics - Open</i> , 2019, 3, 247-254.	0.9	4
67	Treatment of Severe Trigeminal Headache in Patients With Pituitary Adenomas. <i>Neurosurgery</i> , 2011, 68, 1300-1308.	0.6	3
68	A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 87-105.	0.3	3
69	Long-term real-life outcomes in a georefered cohort of acromegalic patients in Brazil. <i>Endocrine</i> , 2020, 68, 390-398.	1.1	3
70	Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study. <i>JMIR Research Protocols</i> , 2021, 10, e24211.	0.5	3
71	Relações de comercialização entre compradores e produtores de leite do sul de Minas Gerais. <i>Interações (Campo Grande)</i> , 0, , 207-220.	0.1	3
72	A novel mutation of thyroid hormone receptor beta (I431V) impairs corepressor release, and induces thyroid hormone resistance syndrome. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2008, 52, 1304-1312.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. <i>European Journal of Endocrinology</i> , 2012, 167, 887-887.	1.9	2
74	Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow-up. <i>Clinical Diabetes and Endocrinology</i> , 2021, 7, 6.	1.3	2
75	Persistence of hyperprolactinemia after treatment of primary hypothyroidism and withdrawal of long term use of estrogen: are the tuberoinfundibular dopaminergic neurons permanently lesioned?. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2005, 49, 468-472.	1.3	1
76	Entropy and uniformity as additional parameters to optimize the effectiveness of bone CT in the evaluation of acromegalic patients. <i>Endocrine</i> , 2020, 69, 368-376.	1.1	1
77	Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
78	Characteristics of patients with pituitary gigantism: results of an international study. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
79	Cognitive behavioral therapy adapted for patients with acromegaly. <i>Current Psychology</i> , 0, , .	1.7	0